All Type of News
Boehringer acquires Korean approval of IPF treatment ‘Ofev’Boehringer Ingelheim Korea(CEO Ki-Hwan Park) announced acquisition of product approval for its idiopathic pulmonary fibrosis(IPF) treatment, Ofev Soft Cap(generic name: nintedan...
|
Active start on export of Celltrion’s antibody biosimilar Remsima to U.S.A Celltrion’s affiliate, Celltrion Healthcare announced it will begin to export Remsima(U.S. product name: Inflectra) from its release data on November.
Through its joint news ...
|
Rebate activities will eventually bring back negative impacts
“In the past, we had to have rebate activities to survive, but now we have to stop them to survive.”
This was a well-known statement among CEOs in the pharmaceutical industry after enforcements of the ‘Rebate Two-Out...
MFDS’s plan to recruit large number of doctors
The Ministry of Food and Drug Safety(MFDS) is discussing a plan to recruit doctors as examiners to evaluate Korean pharmaceutical approvals for synthesized drugs and biomedicines.
It was known the ministry is plannin...
No. of pharmacies was 21,267 in 2015, increased by 209
The Health Insurance Review & Assessment Service(Director Myung-Sae Sohn) and the National Health Insurance Service(President Sang-Cheol Sung) published the ‘2015 Year Book for National Health Insurance Statistics’ wh...
2 of 5 listed pharmas have more than 2 CEOs
2 of 5 listed pharmaceutical companies were known to run their companies with more than 2 CEOs.
With the purpose to responsibly run their company by sharing roles between the largest shareholder and professional mana...
Pharma industry about Kim Young-Ran Law, “Company’s excessive pressure causes adverse effect”
The 28th of October will be the day the Kim Young-Ran Law has been enforced for a month.
Known as the ‘Bribery Prohibition Law,’ the law, which has brought both positive and negative impacts across the nation, has al...
Co-promotion of ‘low-profit products’ issued
While co-promotion agreements between foreign and Korean pharmaceutical companies have been made this year, the industry has kept raising complaints that multinational companies only consign low-profit products with l...
“Why Korean companies ignore KRW 130 billion ‘Lipitor’”
While the complex market with statin has led the industry, Korean pharmaceutical companies are known to focus, especially, on R&D for ‘Crestor(generic name: rosuvastatin).’
In this way, the market of combined drugs w...
Will trio for ‘2nd Novartis’ rebate investigation kick off?
It was analyzed the prosecution and police, Ministry of Health and Welfare will carry out a rebate investigation that is similar to the one for Novartis Korea announced last August. Although the police are currently k...
